KineMed Inc. granted Merck & Co. Inc. nonexclusive rights to identify and develop up to 10 compounds for atherosclerosis using its reverse cholesterol transport (RCT) technology, in exchange for more than $5.5 million in initial and research payments and up to $70 million in milestones per compound. (BioWorld Today) Read More
